



IX Congresso Internacional de
Uro-Oncologia



IV SIMPÓSIO MULTIPROFISSIONAL DE URO-ONCOLOGIA

Sessão Fuzilamento

Dr. Felipe Moraes

Oncologista clínico-BP





Docetaxel + Castração

Deve ser o padrão de cuidados para pacientes com câncer de próstata metastático dependente de androgênio






Figure: The Prostate Cancer Continuum. ADT = androgen deprivation therapy. RT = radiation therapy.

História natural do câncer de próstata



O câncer sempre encontra um meio?





Podemos alterar esse processo?

We Can Do It!




Docetaxel

STAMPEDE


CHAARTED

STAMPEDE




A= 1200 pcts => ~404 eventos de medição de desfechos primários
 B= ~600 pcts, C= ~600 pcts, E= ~600 pcts


STAMPEDE – Sobrevida global M1



CHAARTED



All Patients



CHAARTED

SG 13,6 meses

No. at Risk

ADT+docetaxel	397	333	189	89	46	5	2	0
ADT alone	393	318	168	71	27	3	1	0


HR=0,61 (0,47-0,80) p=0,0003

Mediana de SG

ADT + D: 57,6 meses

ADT isolada: 44,0 meses

Patients with High-Volume Disease



No. at Risk

ADT+docetaxel	263	213	123	56	31	5	2	0
ADT alone	250	193	92	40	14	3	1	0

CHAARTED


SG

17 meses

Alto volume

p=0,0006
 HR=0,60 (0,45-0,81)
 Mediana de SG
 ADT + D: 49,2 meses
 ADT isolada: 32,2 meses

Análise conjunta dos estudos



Conclusões

Em pacientes com idade muito avançada, comorbidades e pouco volume da doença o benefício de docetaxel é menor, pela toxicidade associada.

Nos demais pacientes, particularmente naqueles com doença de grande volume, docetaxel em associação com ADT aumentou sobrevida global, demonstrando claramente seu benefício.



Hold your fire!

Abi x Docetaxel

Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis

Metanálise: 6067 pacientes

HR DOCE+ADT: 0,75 (IC 95%: 0,63-0,94)

HR AB+ADT: 0,64 (IC 95%: 0,55-0,72)

Comparação entre eles: HR 0,84 (IC 95%: 0,67-1,06) – sem diferença estatística.

Abi x Docetaxel

Nenhuma diferença estatisticamente diferente em nenhum subgrupo



	Doce-ADT vs ADT alone			Abi-ADT vs ADT alone			Abi-ADT vs Doce-ADT HR (95% CI)
	Studies	HR (95% CI)	I ² (%)	Studies	HR (95% CI)	I ² (%)	
Overall	3	0.75 (0.63–0.91)	51	2	0.63 (0.55–0.72)	0	0.84 (0.67–1.06)
Disease volume	High	2	0.68 (0.52–0.87)	25	1	0.60 (0.47–0.75)	NA
	Low	2	0.83 (0.50–1.37)	47	1	0.65 (0.45–0.96)	NA
Age	Younger	2	0.71 (0.60–0.85)	0	2	0.55 (0.45–0.66)	0
	Older	2	0.65 (0.32–1.33)	77	2	0.77 (0.53–1.12)	71
Performance Status	0	2	0.75 (0.63–0.91)	0	2	0.67 (0.56–0.80)	0
	1–2	2	0.59 (0.32–1.10)	78	2	0.57 (0.46–0.71)	0
Gleason Score	≤7	2	0.55 (0.35–0.89)	27	2	0.74 (0.48–1.15)	0
	≥8	2	0.70 (0.56–0.87)	29	2	0.61 (0.53–0.71)	0
Recurrent disease	Yes	3	0.74 (0.48–1.15)	0	1	0.94 (0.35–2.52)	NA
	No	3	0.78 (0.66–0.92)	24	1	0.61 (0.50–0.74)	NA
Visceral disease	Yes	1	0.52 (0.25–1.07)	n/a	1	0.51 (0.33–0.79)	NA
	No	1	0.64 (0.46–0.89)	n/a	1	0.66 (0.53–0.83)	NA

Abi = abiraterone acetate; ADT = androgen deprivation therapy; CI = confidence interval; Doce = docetaxel; HR = hazard ratio; NA = not applicable.

Abi x Docetaxel



Docetaxel

O tratamento com Docetaxel tem duração limitada no tempo, facilitando a logística, custos e suporte ao paciente.



Abiraterona

TEMPO TOXICIDADE


Conclusões

Comparações estatísticas: Abi+ADT = Doce+ADT, falta fase III.

Docetaxel é de fácil acesso na realidade brasileira.

Docetaxel tem duração definida.

O sequenciamento terapêutico que ainda não foi esclarecido.




Preparar... Apontar...



Mais pancada
na
abiraterona...

AR-V7

Full-Length AR (AR-FL)



Mutação de resistência a abiraterona

Cerca de 10% dos pacientes


Ainda não selecionamos esses pacientes.

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

AR-V7

Emmanuel S. Antonarakis, M.D., Changxue Lu, Ph.D., Hao Wang, Ph.D.,


Abiraterone-Treated Patients



No. at Risk

AR-V7 negative	25	10	5	0
AR-V7 positive	6	1	0	0

Abiraterone-Treated Patients



No. at Risk

AR-V7 negative	25	11	5	0
AR-V7 positive	6	2	0	0

Acabou...

